Ślusarczyk, Aleksander;
Gurwin, Adam;
Barnaś, Anna;
Ismail, Hamza;
Miszczyk, Marcin;
Zapała, Piotr;
Przydacz, Mikołaj;
... Section of Urologic Oncology of Polish Urological Association; + view all
(2025)
Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies.
European Urology Oncology
10.1016/j.euo.2025.02.003.
(In press).
![[thumbnail of Kasivisvanathan_PCa focal therapy manuscript_revised_R2.pdf]](https://discovery.ucl.ac.uk/style/images/fileicons/text.png) |
Text
Kasivisvanathan_PCa focal therapy manuscript_revised_R2.pdf Access restricted to UCL open access staff until 3 January 2026. Download (370kB) |
Abstract
BACKGROUND AND OBJECTIVE: Focal therapies (FTs) for localized prostate cancer (PCa) are recommended only within prospective registries or clinical trials. In this systematic review and meta-analysis, we aimed to synthesize data from prospective trials evaluating the efficacy and safety of FTs in patients with clinically localized PCa. METHODS: Systematic searches of the PubMed, Scopus, and Web of Science databases identified prospective studies reporting oncological outcomes of FTs in treatment-naïve, clinically localized PCa patients. The primary endpoint was biopsy-proven clinically significant PCa (csPCa; International Society of Urological Pathology grade group ≥2) recurrence-free survival (csPCa RFS). The secondary endpoints included RFS, radical/systemic treatment-free survival, and adverse event (AE) rates. KEY FINDINGS AND LIMITATIONS: Fifty studies including 4615 patients treated with FTs were analyzed; of these 50 studies, 19 were on predominantly intermediate-risk (n = 2800), 16 on mixed low-/intermediate-risk (n = 990), and 15 on low-risk (n = 825) patients. Estimates of 12- and 24-mo csPCa RFS rates were 86% (95% confidence interval [CI] 82-89%) and 81% (95% CI: 74-86%), respectively. In the intermediate-risk subgroup, the 12-mo csPCa RFS rate was 79% (95% CI: 74-83%). Five-year radical and systemic treatment-free survival was 82% (95% CI: 75-88%). The pooled incidence of grade ≥3 AEs was 3% (95% CI: 2-5%). Pad-requiring urinary incontinence increased by 3% (95% CI: 0-6%), with 11% of patients developing new erectile dysfunction (95% CI: 4-18%). The median follow-up of 21 mo (interquartile range 12-34) and the use of surrogate endpoints constitute the major limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: The primarily short-term data from prospective studies of FT in clinically localized PCa demonstrate moderate to high cancer control with a favorable safety profile.
| Type: | Article |
|---|---|
| Title: | Outcomes of Focal Therapy for Localized Prostate Cancer: A Systematic Review and Meta-analysis of Prospective Studies |
| Location: | Netherlands |
| DOI: | 10.1016/j.euo.2025.02.003 |
| Publisher version: | https://doi.org/10.1016/j.euo.2025.02.003 |
| Language: | English |
| Additional information: | This version is the author accepted manuscript. For information on re-use, please refer to the publisher’s terms and conditions. |
| Keywords: | Ablation techniques, Focal ablation, Progression, Prostate cancer, Prostatic neoplasm, Recurrence |
| UCL classification: | UCL UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences UCL > Provost and Vice Provost Offices > School of Life and Medical Sciences > Faculty of Medical Sciences > Div of Surgery and Interventional Sci |
| URI: | https://discovery.ucl.ac.uk/id/eprint/10210638 |
Archive Staff Only
 |
View Item |
